You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FLAG-IDA

Showing 1 - 25 of 227
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Leukemia, Acute Myeloid (AML) Trial (Clifutinib, LoDAC, Azacitidine)

Not yet recruiting
  • Leukemia, Acute Myeloid (AML)
  • (no location specified)
Oct 16, 2022

Acute Myeloid Leukemia, Myeloid Tumor Trial in Seattle (Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myeloid Neoplasm
  • Biospecimen Collection
  • +9 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 5, 2023

Acute Myeloid Leukemia Trial in Poland, United States (A arm (DA-90), B arm (DAC), A arm (CLAG-M))

Recruiting
  • Acute Myeloid Leukemia
  • A arm (DA-90)
  • +3 more
  • New York, New York
  • +9 more
Sep 30, 2021

Acute Myeloid Leukemia Trial in Spain (Quizartinib, Fludarabine, Cytarabine)

Active, not recruiting
  • Acute Myeloid Leukemia
  • Alicante, Spain
  • +19 more
Mar 11, 2022

Acute Myeloid Leukemia Trial in Spain (Selinexor, fludarabine, idarubicin)

Completed
  • Acute Myeloid Leukemia
  • Badalona, Spain
  • +3 more
May 19, 2020

AML, AML With Mutated NPM1, Hematologic Malignancy Trial (Ziftomenib, Fludarabine, Idarubicin)

Not yet recruiting
  • AML
  • +11 more
  • (no location specified)
Aug 14, 2023

Refractory Hematologic Cancer, Allogeneic Stem Cell Transplantation Trial in Shanghai (CLAGE-FluBu)

Active, not recruiting
  • Refractory Hematologic Cancer
  • Allogeneic Stem Cell Transplantation
  • Shanghai, China
    Blood & Marrow Transplantation Center, RuiJin Hospital
Nov 23, 2021

Acute Myeloid Leukemia Trial in Worldwide (guadecitabine, Treatment Choice (TC))

Completed
  • Acute Myeloid Leukemia
  • Los Angeles, California
  • +94 more
Sep 5, 2021

Leukemia, Acute Myeloid (AML) Trial in Worldwide (gilteritinib, LoDAC (Low Dose Cytarabine), Azacitidine)

Active, not recruiting
Has Results
  • Leukemia, Acute Myeloid (AML)
  • Birmingham, Alabama
  • +125 more
Aug 9, 2022

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission Trial in São Paulo (Bortezomib)

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • Acute Lymphoblastic Leukemia With Failed Remission
  • São Paulo, SP, Brazil
    Instituto do Cancer do Estado de Sao Paulo
Sep 12, 2023

Acute Leukemia Trial in Shanghai (intensive chemo - RIC preparation)

Completed
  • Acute Leukemia
  • intensive chemo - RIC preparation
  • Shanghai, China
    Blood & Marrow Transplantation Center, RuiJin Hospital
Mar 18, 2019

AML Trial in Moscow (allo-HSCT)

Recruiting
  • AML
  • allo-HSCT
  • Moscow, Russian Federation
    National Research Center for Hematology
Apr 14, 2022

Acute Myeloid Leukaemia, Myelodysplastic Syndrome Trial in Denmark, United Kingdom (Arm A Mylotarg plus DA Versus CPX-351, Arm B

Unknown status
  • Acute Myeloid Leukaemia
  • Myelodysplastic Syndrome
  • Arm A Mylotarg plus DA Versus CPX-351
  • +5 more
  • Aalborg, Denmark
  • +86 more
Jan 22, 2020

Acute Myeloid Leukemia, Venetoclax Trial in Kunming (combination of venetoclax and HAA regimen)

Recruiting
  • Acute Myeloid Leukemia
  • Venetoclax
  • combination of venetoclax and HAA regimen
  • Kunming, Yunnan, China
    The Second Affiliated Hospital of Kunming Medical University.
May 29, 2023

Acute Myeloid Leukemia Trial in Kunming (Venetoclax in Combination With Azacitidine and HA Regimen)

Recruiting
  • Acute Myeloid Leukemia
  • Venetoclax in Combination With Azacitidine and HA Regimen
  • Kunming, Yunnan, China
    The Second Affiliated Hospital of Kunming Medical University.
Jul 10, 2023

Leukemia, Myeloid, Acute Trial in United States (DFP-10917, Cytarabine, Azacitidine)

Recruiting
  • Leukemia, Myeloid, Acute
  • Birmingham, Alabama
  • +38 more
Dec 25, 2021

Acute Myeloid Leukemia Trial in Houston (Crenolanib besylate, Idarubicin, Cytarabine)

Completed
  • Acute Myeloid Leukemia
  • Crenolanib besylate
  • +7 more
  • Houston, Texas
    MD Anderson Cancer Center
Jul 17, 2020

Elderly AML Patients, Unfit, New-diagnosis AML, Acute Myeloid Leukemia Trial in Kunming (Experimental: Venetoclax in combination

Not yet recruiting
  • Elderly AML Patients
  • +4 more
  • Experimental: Venetoclax in combination with Decitabine (+-sorafenib)
  • Active Comparator: Standard dose of Venetoclax + Azacitidine
  • Kunming, Yunnan, China
    The Second Affiliated Hospital of Kunming Medical University.
Oct 3, 2023

Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations Trial in Worldwide (Crenolanib, Cytarabine,

Recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
  • Sacramento, California
  • +61 more
Apr 28, 2021

Acute Myeloid Leukemia, Adult Trial in La Plata, Caba (Evaluation of first line treatment with intensive treatment outcome in

Recruiting
  • Acute Myeloid Leukemia, Adult
  • Evaluation of first line treatment with intensive treatment outcome in adult patients with AML.
  • La Plata, Buenos Aires, Argentina
  • +1 more
Nov 9, 2021

Acute Myeloid Leukemia Trial in Minsk (NK cell infusions)

Recruiting
  • Acute Myeloid Leukemia
  • NK cell infusions
  • Minsk, Minsk Region, Belarus
    Belarussian Research Center for Pediatric Oncology, Hematology a
Feb 28, 2022

Acute Lymphoblastic Leukemia Trial in Spain (Pediatric-type of chemo, allogeneic HSCT)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Pediatric-type of chemotherapy
  • allogeneic HSCT
  • Badalona, Barcelona, Spain
  • +107 more
Feb 17, 2022

Hemiplegia and Hemiparesis Trial in Lamía (Therapeutic Climbing)

Active, not recruiting
  • Hemiplegia and Hemiparesis
  • Therapeutic Climbing
  • Lamía, Phthiotis, Greece
    Department of Physiotherapy
Aug 6, 2023

Clinical Pre-hospital "Red- Flag" Alert for Activation of

Not yet recruiting
  • Trauma Injury
    • (no location specified)
    Apr 6, 2023

    Leukemia, Myeloid, Acute Trial (Cytarabine, Venetoclax, CPX-351)

    Not yet recruiting
    • Leukemia, Myeloid, Acute
    • (no location specified)
    Nov 25, 2022